Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines
Chronic infections with HBV and HCV continue to be major public health problems, with hundreds of millions of people infected worldwide; this is despite the availability of both an effective prophylactic HBV vaccine for more than 3 decades and potent direct antivirals for HBV and, more recently, HCV...
Saved in:
Main Authors: | Almudena Torres-Cornejo (Author), Georg M. Lauer (Author) |
---|---|
Format: | Book |
Published: |
Case Western Reserve University,
2017-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine
by: Cristina Stasi, et al.
Published: (2016) -
Heme and HO-1 inhibition of HCV, HBV, and HIV
by: Warren N Schmidt, et al.
Published: (2012) -
THE CYTOKINE IP-10 IN CHRONIC HBV AND HCV INFECTION
by: Nina S. Nikolova, et al.
Published: (2013) -
HBV, HCV co-infection among blood donors in Nigeria
by: Opaleye O, et al.
Published: (2010) -
Prevalence of HBV and HCV Infections and Associated Risk Factors in Addict Prisoners
by: AA Javadi, et al.
Published: (2006)